



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Summary of Main Points from the Meeting held on Monday 10<sup>th</sup> April 2017**

**2. Minutes and Summary Notes from last meeting**

The Minutes and Summary notes from the March 2017 Medicines Group meeting were approved and will be circulated.

**3. Matters Arising**

The Group noted the matters arising from the previous meeting.

**4. Business to be transacted by the Medicines Group**

**4.1 Formulary Applications**

***Full applications***

• **Dexmedetomidine 200mcg/2ml injection (Dexdor<sup>®</sup>) intranasal**

Licensed for sedation in adult patients requiring a sedation level not deeper than arousal in response to verbal stimulation. Requested by General Paediatrics as a premedication prior to anaesthesia in children with learning difficulties (e.g. autism) who are unsuitable for oral / buccal sedation. Also requested as a premedication for children undergoing skin laser therapy. Advantages include: Route of administration is easier for this cohort of patients, midazolam intranasal can cause stinging and there is a decreased incident of Emergence Delirium.

**Decision: Approved for off-label use within the Trust**

***Ex-Panel Requests***

• **Ticagrelor 60mg Tablets (Brilique<sup>®</sup>)**

Brilique 60 mg twice daily is the recommended dose when an extended treatment is required for patients with a history of MI of at least one year and are at high risk of an atherothrombotic event. 90mg tablets already on formulary.

**Decision: Approved for addition to the formulary**

***NICE TA Approved Requests***

• **Ibrutinib 140mg Capsules (Imbruvica<sup>®</sup>)**

For use in line with NICE TA429 (Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation).

**Decision: Approved for addition to the formulary**

***Pharmacoeconomic Board Requests***

• **IFR - Infliximab IV for relapsing Polychondritis**

Requested by the Rheumatology Team for a patient with relapsing Polychondritis (off-label use)  
Approved by the Pharmacoeconomic Board on 15/03/17.

**Decision: Noted**

• **IFR - Infliximab IV for Neurosarcoidosis**

Requested by the Ophthalmology Team for a patient with Neurosarcoidosis (Ocular sarcoid) which has been refractory to ciclosporin and mycophenolate combined.  
Approved by the Pharmacoeconomic Board on 28/02/17.

**Decision: Noted**

**4.2 Trust Medicines Policy**

• **Plan for unification of the Trust Medicines Policies at both hospital sites**

The timeline for unification of the Trust Medicines Policies at both sites was presented. The unification process involves reviewing the relevant sections that are currently in place at both sites and identifying areas of difference. A review will then take place to agree the unified process going forward and to produce a unified



## Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

policy. Each unified section of the policy will be presented at the Trust Medicines Group meeting for ratification with an accompanying sheet that details of any changes in policy that specifically affect each site. This will then be used for communicating the change in policy following ratification.

The plan spreadsheet presented was updated as of April 2017. Current status: After TMG April meeting 31/33 (94%) sections will have been updated and harmonised across both sites. Harmonised sections of the Trust Medicines Policy are now available on the new Trust Intranet web site.

**Decision: Noted**

- **TMP Section 2: Prescribing**

Harmonised policy

**Decision: Approved**

- **TMP Section 32: In-patient self-administration of medicines**

Harmonised policy.

**Decision: Approved**

- **Memo re. Doctor's personal prescriptions**

There will no longer be a provision for doctors employed by the Trust to self-prescribe or prescribe for members of their immediate family at the Chelsea & Westminster Hospital site. This historically has been common practice in accordance to the former Trust Medicines Policy - Section 17 Doctor's personal prescriptions. A memo has been drafted detailing the change and was approved for dissemination Trustwide. This will be disseminated on 11<sup>th</sup> April and the change will come into effect from 17<sup>th</sup> April. The Trust Medicines Policy Section 15 - Doctor's personal prescriptions will be removed and replaced with a small paragraph in Section 2 - Prescribing.

**Decision: Approved**

- **TMP Section 30: Supply of Discharge Medicines Packs by Nurses/Midwives from Wards/Departments**

Updated to include Burns Unit as a clinical area that can work under this policy.

**Decision: Approved**

- **TMP Section 28: Controlled Drugs Governance Arrangements**

Updated to include change of details of the Trust Controlled Drug Accountable Officer.

**Decision: Approved**

### **4.3 Medicines Optimisation**

- **GP Information leaflet: NSAIDs and Cox-2 Inhibitors**

Newly compiled information leaflet for GPs relating to NSAIDs and Cox-2 Inhibitor.

Compiled for the attention of: GPs managing patients newly initiated on or who are due to be started on a NSAID / COX-2 Inhibitor.

It was requested that this leaflet is forwarded to the relevant CCG Medicines Management meetings for approval.

**Decision: Noted but further approval required**

### **4.4 NICE TA Guidance**

**NICE TA Guidance - March 2017**

**4 Appraisals were published in March 2017**

- **TA434 - Elotuzumab for previously treated multiple myeloma**

**Action: Nil - No recommendation**

- **TA435 - Tenofovir alafenamide for treating chronic Hepatitis B**

**Action: Nil - No recommendation**



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

- **TA436 - Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer**  
**Action: Nil - No recommendation**

- **TA437 - Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy**  
**Action: Nil - No recommendation**

**a) NICE TA Adherence Table 2016/17**

NICE TA Adherence Table for 2016/17 was noted and will be uploaded onto the Trust Internet available for public viewing.

**4.5 IVIG Update**

- **IVIG requests**

**March 2017**

**CWH Site**

There were 17 IVIG issues, with 8 new requests

**WMUH Site**

There were 18 IVIG issues, with 7 new requests

**Decision: Approved**

**4.6 Items for noting**

- **MHRA Update - March 2017**

**Decision: Noted**

**4.7 Meeting minutes for noting**

- **Antimicrobial Steering Group Meeting minutes - February 2017**

Minutes from meeting held in February 2017

**Decision: Noted**

- **Local Chemotherapy Group - February 2017**

Minutes from meeting held in February 2017

**Decision: Noted**

**Clinical Chemotherapy Service Group (CCSG) Meeting minutes - March 2017**

Minutes from meeting held in March 2017

**Decision: Noted**

**4.8 Additional papers to go to Trust patient Safety Group**

- **Nil**

**5. Any other business**

**Trust Controlled Drug Accountable Officer**

The new Trust Controlled Drug Accountable Officer was announced.

**6. Date of next meeting**

**Next meeting**

**Date: Monday 8<sup>th</sup> May 2017**



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Time: 8am-9am**

**Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)**

**Closing date: 14<sup>th</sup> April 2017**